长期从事人类重大疾病生物治疗，针对实体瘤免疫抑制微环境导致治疗抵抗、复发转移等临床难题，开展肿瘤微环境调控及生物技术药物研发，包括溶瘤病毒重塑微环境、肿瘤疫苗诱导抗肿瘤免疫及新型免疫细胞治疗策略优化；同时，针对新发突发及慢性感染性疾病（如呼吸道病毒、HPV）疫苗研发瓶颈，设计高效广谱疫苗以解决病原变异快、保护持久性不足等临床困境。研究致力于推动从基础发现向临床转化，为改善肿瘤及感染性疾病患者预后提供创新方案。作为课题负责人承担了“重大新药创制”国家科技重大专项、艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项、国家自然科学基金、四川省科技支撑计划、教育部博士点基金等多项课题。以第一/通讯作者（含并列）在Nature Biomedical Engineering、Signal Transduction and Targeted Therapy、Molecular Cancer、Biomaterials、Experimental Hematology & Oncology、Journal for Immunotherapy of Cancer、Molecular Therapy、Acta Biomaterialia、MedComm等期刊发表高水平论文40余篇，获授权专利8项。主持开发了3个具有自主知识产权的国家一类新药，相关技术已成功转让给企业，并与企业联合开展后续开发，目前均已申报或正筹备申报Ⅰ期临床试验。
四川省免疫学会肿瘤免疫专委会委员
四川省肿瘤学会基因与免疫细胞治疗专委会委员
1. W. Hong, P. Cheng, J. Yang, H. Shi, Z. Wang, J. Li, H. Lei, D. Peng, C. He, W. Ren, X. Pan, Y. Huang, A. Alu, F. Qin, B. Wang, Y. Zhou, Y. Yang, W. Yu, C. Tang, Q. Huang, M. Yang, B. Li, J. Li, J. Wang, J. Ai, L. Chen, H. Que, Z. Zeng, J. Liu, Y. Hao, D. Ao, Y. Zhang, X. Huang, C. Ye, M. Fu, X. He, Z. Bi, X. Han, M. Luo, H. Hu, W. Cheng, H. Dong, J. Lei, L. Chen, X. Zhou, W. Wang, G. Shen, J. Yang, X. Song, Y. Wei, S. Lu, Q. Sun, G. Lu, Y. Wang, L. Yang, W. Li, X. Wei, Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant. Nat. Biomed. Eng. (2025), doi:10.1038/s41551-025-01517-2.（并列第一作者）
2. S. Hu, J. Xu, Z. Wang, Y. Zhang, C. Zhao, Y. Liu, F. Luo, P. Cheng, J. Wang, J. Zhao, SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication. J. Immunother. Cancer 14, e013550 (2026).（并列通讯作者）
3. C. Su, L. Song, X. Wang, Y. Zhou, M. Chen, T. Xu, L. Huang, Y. Ma, Z. Xu, S. Hu, Z. Qi, D. Luo, Z. Yang, X. Chen, G. Yang, Q. He, L. Xiong, P. Cheng, J. Jing, H. Shi, Blockade of metastasis by targeting circulating tumor cells with platelet encapsuled oncolytic adenovirus. Biomaterials 326, 123674 (2026). （并列通讯作者）
4. B. Xiao, Q. Yang, S. Hu, J. Hu, Z. Qi, Y. Zhang, Y. Qin, P. Cheng, Enhancing Oncolytic Adenovirus Replication by Early Region 1A Protein‐Mediated Degradation of E1A Binding Protein p300. MedComm 7, e70683 (2026). （唯一通讯作者）
5. Y. Zhang, K. Qiu, J. Ren, Y. Zhao, P. Cheng, Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct. Target. Ther. 10, 44 (2025). （并列通讯作者）
6. Y. Fu, B. Wang, A. Alu, W. Hong, H. Lei, X. He, H. Shi, P. Cheng, X. Yang, Immunosenescence: signaling pathways, diseases and therapeutic targets. Signal Transduct. Target. Ther. 10, 250 (2025). （并列通讯作者）
7. Z. Qi, S. Hu, J. Zhao, X. Xu, A. Huang, Y. Qin, Y. Zhang, Q. Yang, J. Hu, C. Su, P. Cheng, CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity. Exp. Hematol. Oncol. 14, 106 (2025). （唯一通讯作者）
8. J. Zhao, S. Hu, Z. Qi, X. Xu, X. Long, A. Huang, J. Liu, P. Cheng, Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity. J. Immunother. Cancer 12, e009768 (2024). （并列通讯作者）
9. W. Hong, H. Lei, D. Peng, Y. Huang, C. He, J. Yang, Y. Zhou, J. Liu, X. Pan, H. Que, A. Alu, L. Chen, J. Ai, F. Qin, B. Wang, D. Ao, Z. Zeng, Y. Hao, Y. Zhang, X. Huang, C. Ye, M. Fu, X. He, Z. Bi, X. Han, M. Luo, H. Hu, W. Cheng, H. Dong, J. Lei, L. Chen, X. Zhou, W. Wang, G. Lu, G. Shen, L. Yang, J. Yang, J. Li, Z. Wang, X. Song, Q. Sun, S. Lu, Y. Wang, P. Cheng, X. Wei, A chimeric adenovirus‐vectored vaccine based on Beta spike and Delta RBD confers a broad‐spectrum neutralization against Omicron‐included SARS‐CoV‐2 variants. MedComm 5, e539 (2024). （并列通讯作者）
10. J. Ma, C. Zhang, G. Shi, D. Yue, Y. Shu, S. Hu, Z. Qi, Y. Chen, B. Zhang, Y. Zhang, A. Huang, C. Su, Y. Zhang, H. Deng, P. Cheng, High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment. Mol. Ther. 30, 644–661 (2022). （唯一通讯作者）
11. L. Cheng, S. Hu, J. Ma, Y. Shu, Y. Chen, B. Zhang, Z. Qi, Y. Wang, Y. Zhang, Y. Zhang, P. Cheng, Long noncoding RNA RP11-241J12.3 targeting pyruvate carboxylase promotes hepatocellular carcinoma aggressiveness by disrupting pyruvate metabolism and the DNA mismatch repair system. Mol. Biomed. 3, 4 (2022). （唯一通讯作者）
12. S. Hu, J. Ma, C. Su, Y. Chen, Y. Shu, Z. Qi, B. Zhang, G. Shi, Y. Zhang, Y. Zhang, A. Huang, Y. Kuang, P. Cheng, Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 135, 567–581 (2021). （唯一通讯作者）
13. B. Zhang, P. Cheng, Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy. Mol. Cancer 19, 158 (2020). （唯一通讯作者）
14. Y. Shu, P. Cheng, Targeting tumor-associated macrophages for cancer immunotherapy. Biochim. Biophys. Acta BBA - Rev. Cancer 1874, 188434 (2020). （唯一通讯作者）
研究生部公众号
川公网安备51010702002012